Deletion of nuoG from the Vaccine Candidate Mycobacterium bovis BCG ΔureC::hly Improves Protection against Tuberculosis.
about
Sleeping Beauty and the Story of the Bacille Calmette-Guérin VaccineListeria monocytogenes-Induced Cell Death Inhibits the Generation of Cell-Mediated Immunity.Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa.Immune Responses to Bacillus Calmette-Guérin Vaccination: Why Do They Fail to Protect against Mycobacterium tuberculosis?A Herpes Simplex Virus Type 2 Deleted for Glycoprotein D Enables Dendritic Cells to Activate CD4+ and CD8+ T Cells.NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans.Mycobacterium tuberculosis Lipoprotein MPT83 Induces Apoptosis of Infected Macrophages by Activating the TLR2/p38/COX-2 Signaling Pathway.The Recombinant Bacille Calmette-Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing.TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical DevelopmentEfficacy Testing of H56 cDNA Tattoo Immunization against Tuberculosis in a Mouse Model.Plasticity of Mycobacterium tuberculosis NADH dehydrogenases and their role in virulence.The Macrophage: A Disputed Fortress in the Battle against Mycobacterium tuberculosis.Next-Generation Vaccines Based on Bacille Calmette-Guérin.Deletion of BCG Hip1 protease enhances dendritic cell and CD4 T cell responses.Consequence of enhanced LC3-trafficking for a live, attenuated M. tuberculosis vaccine.The current status, challenges, and future developments of new tuberculosis vaccines.Development of New Preventive and Therapeutic Vaccines for Tuberculosis.
P2860
Q37208406-95D2E44C-B73B-4904-802A-C3CF04122668Q37546999-3081B49B-76F2-4811-B19A-57C1D9D46FB7Q37633072-1FBA96CE-6579-4F33-AC30-B8A1A26C8F74Q37737607-259C7A76-AAA8-4B30-BE19-904DD32FC250Q40067153-F058E74C-AEB8-47B3-A029-8D45E7B44503Q40087530-88FE1AF5-1062-43BD-8CAC-8053AE3548CDQ40211803-3D3098F4-9AC8-4571-AFDD-5A0AE27B9E17Q41836016-F602E2C1-0804-4267-8D84-D2B7A694C783Q42372774-2C2037B1-93F6-4DA8-8C4C-E193426CA551Q47221323-ADCA3DCA-A759-48EA-AF54-493F3837D8F7Q49571536-2D251674-A62F-442F-9E69-4289C0D97EC3Q49637506-2F30CDEF-A161-445A-864A-FA4B790B7D6FQ49829375-02FEECFA-B708-452B-AE8D-B9E78848D40EQ49973045-E8857575-BC27-4197-80B2-350A08FE97DEQ49990980-9E8C6F3F-11A7-47EB-873C-7B3944F1009AQ52337140-8186C160-AEB9-49CB-BAE2-203C514DED85Q55280574-79D60B45-2784-4086-8AB0-C584368AF217
P2860
Deletion of nuoG from the Vaccine Candidate Mycobacterium bovis BCG ΔureC::hly Improves Protection against Tuberculosis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Deletion of nuoG from the Vacc ...... otection against Tuberculosis.
@en
type
label
Deletion of nuoG from the Vacc ...... otection against Tuberculosis.
@en
prefLabel
Deletion of nuoG from the Vacc ...... otection against Tuberculosis.
@en
P2093
P2860
P50
P356
P1433
P1476
Deletion of nuoG from the Vacc ...... otection against Tuberculosis.
@en
P2093
Doris Lazar
Ina Wagner
Peggy Kaiser
Stefan H E Kaufmann
Stefanie Schuerer
P2860
P356
10.1128/MBIO.00679-16
P577
2016-05-24T00:00:00Z